IBX
pleased to report that the MagSense® HER2 imaging agent Phase 1 study (IBI10103) has achieved its enrolment target and that the Company has iniƟated its plans to close the study as was indicated in the Company’s AGM held on 25th May 2023.
IBXpleased to report that the MagSense® HER2 imaging agent Phase...
-
- There are more pages in this discussion • 229 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)